Literature DB >> 8494725

Detection of bcl-2/JH rearrangement in follicular and diffuse lymphoma: concordant results of peripheral blood and bone marrow analysis at diagnosis.

R Yuan1, P Dowling, E Zucca, H Diggelmann, F Cavalli.   

Abstract

The capacity to detect t(14;18) breakpoints in non-Hodgkin's lymphoma (NHL) peripheral blood and bone marrow was studied by DNA PCR. We studied 33 patients with follicular lymphoma (FL) (Working Formulation subtypes B, C, D) and 38 patients with intermediate-grade NHL (subtypes F, G). In the FL subgroup, 86% of the morphologically-positive bone marrow patients had amplifiable t(14;18) breakpoints by PCR. Remarkably, of 19 FL patients with 'negative' bone marrows, 11 (58%) were PCR-positive. In addition, half of the early clinical stage patients (I and II) had detectable breakpoints in their bone marrow DNA. Samples from NHL patients with intermediate-grade disease exhibit the same phenomena but at a considerably lower frequency. Paired peripheral blood and bone marrow samples were available at diagnosis in a subset of 56 patients. The concordance between bone marrow and peripheral blood PCR findings was high, with peripheral blood of 55/56 showing the same PCR results as the corresponding bone marrow.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8494725      PMCID: PMC1968466          DOI: 10.1038/bjc.1993.171

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  30 in total

1.  Bone marrow involvement in the non-Hodgkin's lymphomata.

Authors:  S A Rosenberg
Journal:  Br J Cancer Suppl       Date:  1975-03

2.  Detection of residual disease in translocation (14;18) positive non-Hodgkin's lymphoma, using the polymerase chain reaction: a comparison with conventional staging methods.

Authors:  A C Lambrechts; P E de Ruiter; L C Dorssers; M B van 't Veer
Journal:  Leukemia       Date:  1992-01       Impact factor: 11.528

3.  Bone marrow involvement in non-Hodgkin's lymphoma: implications for staging and therapy.

Authors:  R S Stein; J E Ultmann; G E Byrne; E M Moran; H M Golomb; N Oetzel
Journal:  Cancer       Date:  1976-02       Impact factor: 6.860

4.  Incidence cytology, and histopathology of non-Hodgkin's lymphomas in the bone marrow.

Authors:  F Dick; C D Bloomfield; R D Brunning
Journal:  Cancer       Date:  1974-05       Impact factor: 6.860

5.  Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18.

Authors:  A Bakhshi; J P Jensen; P Goldman; J J Wright; O W McBride; A L Epstein; S J Korsmeyer
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

6.  Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation.

Authors:  M L Cleary; S D Smith; J Sklar
Journal:  Cell       Date:  1986-10-10       Impact factor: 41.582

7.  Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation.

Authors:  Y Tsujimoto; L R Finger; J Yunis; P C Nowell; C M Croce
Journal:  Science       Date:  1984-11-30       Impact factor: 47.728

8.  Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma.

Authors:  J J Yunis; M M Oken; M E Kaplan; K M Ensrud; R R Howe; A Theologides
Journal:  N Engl J Med       Date:  1982-11-11       Impact factor: 91.245

9.  Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18.

Authors:  M L Cleary; J Sklar
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

10.  Detection of a second t(14;18) breakpoint cluster region in human follicular lymphomas.

Authors:  M L Cleary; N Galili; J Sklar
Journal:  J Exp Med       Date:  1986-07-01       Impact factor: 14.307

View more
  6 in total

1.  Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support.

Authors:  W A Franklin; E J Shpall; P Archer; C S Johnston; S Garza-Williams; L Hami; M A Bitter; R C Bast; R B Jones
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  Association of clinical status of follicular lymphoma patients after autologous stem cell transplant and quantitative assessment of lymphoma in blood and bone marrow as measured by SYBR Green I polymerase chain reaction.

Authors:  Nancy Pennell; Anthony Woods; Marciano Reis; Rena Buckstein; David Spaner; Kevin Imrie; Karen Hewitt; Angela Boudreau; Arun Seth; Neil L Berinstein
Journal:  J Mol Diagn       Date:  2006-02       Impact factor: 5.568

Review 3.  Molecular pathology of low grade malignant lymphomas.

Authors:  H Ratech
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

4.  Detection of minimal residual disease in hematopoietic progenitor cell harvests: lack of predictive value of peripheral blood and bone marrow analysis in mantle cell and indolent lymphoma.

Authors:  Michele Magni; Massimo Di Nicola; Carmelo Carlo-Stella; Paola Matteucci; Liliana Devizzi; Anna Guidetti; Fernando Ravagnani; Alessandro M Gianni
Journal:  Am J Blood Res       Date:  2012-04-15

5.  Clinical relevance of bcl-2(MBR)/J(H) rearrangement detected by polymerase chain reaction in the peripheral blood of patients with follicular lymphoma.

Authors:  F Bertoni; G Bosshard; E Roggero; E Ceresa; F Cavalli; E Zucca
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  A transcriptional signature associated with non-Hodgkin lymphoma in the blood of patients with Q fever.

Authors:  Cléa Melenotte; Soraya Mezouar; Amira Ben Amara; Simon Benatti; Jacques Chiaroni; Christian Devaux; Régis Costello; Guido Kroemer; Jean-Louis Mege; Didier Raoult
Journal:  PLoS One       Date:  2019-06-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.